Identification of genotype-selective anti-tumor agents

Details Identification of genotype-selective anti-tumor agents Identification of genotype-selective anti-tumor agents

2008-04-15

2008-04-15

Canella, Karen A. (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S576000, C514S759000

Reexamination Certificate

active

10767018

ABSTRACT:
The present invention relate to methods of identifying a genotype-selective agent. In certain embodiments, the invention relates to agents that are selectively toxic to engineered human tumorigenic cells.

REFERENCES:
patent: 6831085 (2004-12-01), Bergnes et al.
patent: 2003/0171316 (2003-09-01), Jupe
patent: 2004/0096444 (2004-05-01), Pizzo et al.
patent: 2004/0248221 (2004-12-01), Stockwell
patent: 07-258224 (1995-10-01), None
patent: WO-99/21988 (1999-05-01), None
patent: WO 01/68641 (2001-09-01), None
patent: WO 02/40717 (2002-05-01), None
patent: WO-02/083143 (2002-10-01), None
patent: WO-02/099122 (2002-12-01), None
patent: WO-2004/030615 (2004-04-01), None
patent: WO-2004/055519 (2004-07-01), None
Stedman's Medical Dictionary, 27th Edition, 2000.
Dolma et al (Cancer Cell, Mar. 2003, vol. 3, pp. 285-296).
Ahmed, S. Ansar et al., “A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H] thymidine incorporation assay”, Journal of Immunological Methods, 170(2): 211-224 (1994) (Abstract).
Aiken, C. T., et al., “A cell-Based Screen for Drugs to Treat Huntington's Disease”, Neurobiology of Disease, 16:546-555 (2004).
Andoh, T., et al., “Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I,” Proc Natl Acad Sci U S A, 84:5565-5569 (1987).
Bjornsti, M-A., et al., “Expression of Human DNA Topoisomerase I in Yeast Cells Lacking Yeast DNA Topoisomerase I: Restoration of Sensitivity of the Cells to the Antitumor Drug Camptotchein,”Cancer Res, 49:6318-23 (1989).
Bosch, F.X., et al., “The causal relation between human papillomavirus and cervical cancer,” J Clin Pathol, 55:244-265 (2002).
Brown, E. J., et al., “A mammalian protein targeted by G1-arresting rapamycin-receptor complex,” Nature, 369:756-758 (1994).
Calin, G.A., et al., “Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms,” Oncogene, 19:1191-1195 (2000).
Capdeville, R., et al., “Glivec (STI571, IMATINIB), A Rationally Developed, Targeted Anticancer Drug,”Nat Rev Drug Discov, 1:493-502 (2002).
Champoux, J.J., “Structure-Based Analysis of the Effects of Camptothecin on the Activities of Human Topoisomerase I,” Annals New York Acad Sci, 922:56-64 (2000).
Chan, Y-M, et al., “Caspase inhibitors promote the survival of avulsed spinal motoneurons in neonatal rats,”NeuroReport, 12(3):541-5 (2001).
D'Arpa, P., et al., “Involvement of Nucleic Acid Synthesis in Cell Killing Mechanisms of Topoisomerase Poisons,”Cancer Res, 50:6919-24 (1990).
DeVita, V.T., Jr., et al., “Principles of Cancer Management: Chemotherapy,” Cancer: Principles & Practice of Oncology, Fifth Edition, 333-347 (1997).
Dolma, S, et al., “Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells,” Cancer Cell, 3:285-296 (2003).
Druker, B.J. et al., “Effects of a selective inhibitor of the Abi tyrosine kinase on the growth of Bcr-Abl positive cells”, Nature Medicine, 2:561-566 (1996) (Abstract).
Elenbaas, B. et al., “Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells”, Genes & Development, 15:50-65 (2001).
Eng, W-K, et al., “Evidence that DNA Topoisomerase I Is Necessary for the Cytotoxic Effects of Camptothecin,”Mol Pharmacol, 34:755-60 (1988).
Hahn, W. C. and Weinberg, R. A., “Modelling the Molecular Circuitry of Cancer”, Nature Reviews Cancer, 2:331-341 (2002).
Hahn, W.C., et al., “Creation of human tumor cells with defined genetic elements,” Nature, 400:464-468 (1999).
Hahn, W.C., et al., “Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation,”Mol Cell Biol, 22(7):2111-23 (2002).
Hahn, W.C., et al., “Inhibition of telomerase limits the growth of human cancer cells,” Nat Med, 5(10):1164-1170 (1999).
Hamad, N. M. et al., “Distinct requirements for Ras oncogenesis in human versus mouse cells”, Genes & Development, 16:2045-2057 (2002).
Harley, C.B., “Telomerases,”Pathol Biol(Paris), 42:342-5 (1994).
Hsiang, Y-H. and Liu, L.F., “Identification of Mammalian DNA Topoisomerase I as an Intracellular Target of the Anticancer Drug Camptothecin,”Cancer Res, 48:1722-6 (1988).
Hsiang, Y-H., et al., “Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin,”Cancer Res, 49:5077-82 (1989).
Jorcyk, C.L., et al., “Development and Characterization of a Mouse Prostate Adenocarcinoma Cell Line: Ductal Formation Determined by Extracellular Matrix,” The Prostate, 34:10-22 (1998).
Kohno, T., et al., “Alterations of thePPP1R3Gene in Human Cancer,”Cancer Res, 59:4170-4 (1999).
Laurent, G. and Jaffrezou, J-P., “Signaling pathways activated by daunorubicin,” Blood, 98(4):913-924 (2001).
Lessnick, S.L., et al., “The Ewing's sarcoma oncoprotein EWS/FLI induces a p53- dependent growth arrest in primary human fibroblasts,” Cancer Cell, 1:393-401 (2002).
Liu, L.F., et al., “Mechanism of Action of Camptothecin,” Annals N Y Acad Sci, 922:1-10 (2000).
Loomis, C.R. and Bell, R.M., “Sangivamycin, a Nucleoside Analogue, Is a Potent Inhibitor of Protein Kinase C★,” J Biol Chem, 263(4):1682-1692 (1998).
Madden, K.R., and Champoux, J.J., “Overexpression of Human Topoisomerase I in Baby Hamster Kidney Cells: Hypersensitivity of Clonal Isolates to Camptothecin,”Cancer Res, 52:525-32 (1992).
Majno, G. and Joris, I., “Apoptosis, Oncosis, and Necrosis,”Am J Pathol, 146(1):3-15 (1995).
Makin, G., “Targeting apoptosis in cancer chemotherapy,”Expert Opin Ther Targets, 6(1):73-84 (2002).
Miller, M.L. and Ojima, I., “Chemistry and Chemical Biology of Taxane Anticancer Agents,” Chem. Record, 1:195-211 (2001).
Millward, T.A., et al., “Regulation of protein kinase cascades by protein phosphatase 2A,” Trends Biochem Sci, 24:186-91 (1999).
Mokbel, K. and Hassanally, D., “From HER2 to Herceptin,”Curr Med Res Opin, 17(1):51-9 (2001).
Müler, I., et al:, Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review),Int J Mol Med, 1:491-4 (1998).
Nociari, M.M., et al., “A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity,”J. Immunol. Methods, 213:157-167 (1998).
Pallas, D.C., et al., “Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A,” Cell, 60:167-176 (1990).
Perez-Stable, C., et al., “Prostate Cancer Progression, Metastasis, and Gene Expression in Transgenic Mice,”Cancer Res, 57:900-6 (1997).
Rao, K.V., “Structure of Sangivamycin,”J Med Chem, 11:939-41 (1969).
Rich, J.N., et al., “A Genetically Tractable Model of Human Glioma Formation,”Cancer Res, 61:3556-60 (2001).
Richard, D., et al., “Free radical production and labile Iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell lines,” Leukemia Res, 26:927-931 (2002).
Ruediger, R., et al., “Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the Aβ subunit gene,” Oncogene, 20:1892-1899 (2001).
Ruediger, R., et al., “Disruption of protein phosphatase 2A subunit Interaction in human cancers with mutations in the Aα subunit gene,” Oncogene, 20:10-15 (2001).
Sabatini, D.M., et al., “RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent

Affiliated with

Also associated with

Rating

Identification of genotype-selective anti-tumor agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Identification of genotype-selective anti-tumor agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of genotype-selective anti-tumor agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3953432